EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis

Denis Poddubnyy iD, Bhumik Parikh, Dirk Elewaut iD, Victoria Navarro-Compán, Stefan Siebert iD, Michael Paley iD, Derek Coombs, Ivan Lagunes, Ana Biljan, Priscila Nakasato, Peter Wung, Ennio Lubrano

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Denis Poddubnyy und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Toronto, Toronto, Ontario, Canada, and Charité-Universitätsmedizin, Berlin, Germany. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Heterocyclic Compounds, 3-Ring, Axial Spondyloarthritis, Uveitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the development of extramusculoskeletal manifestations (EMMs) among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with upadacitinib 15 mg.

Methods

Data (cutoff: August 15, 2022) from five clinical trials in PsA (2), radiographic axSpA (r‐axSpA; previously ankylosing spondylitis) (2), and nonradiographic axSpA (nr‐axSpA) (1) were analyzed. Treatment‐emergent adverse events of EMMs including uveitis, inflammatory bowel disease (IBD), and psoriasis were assessed in patients treated with placebo, upadacitinib 15 mg, or adalimumab (PsA only) and are reported as exposure‐adjusted event rates (events per 100 patient‐years [E/100 PY]).

Results

Most patients (87.1%–99.3%) did not have a history of EMMs at baseline. In PsA, development of uveitis and IBD were low regardless of treatment or prior EMM history; rates were similar with upadacitinib 15 mg and adalimumab. In r‐axSpA, development of uveitis was numerically lower (E/100 PY) in patients treated with upadacitinib 15 mg (2.8) versus placebo (7.5) and in patients with no history of uveitis (upadacitinib 15 mg 0.6; placebo 1.2) versus a history of uveitis (upadacitinib 15 mg 2.1; placebo 6.2); occurrence of IBD and psoriasis were low regardless of treatment or history. In nr‐axSpA, development of uveitis was low regardless of history but was numerically lower in patients treated with upadacitinib 15 mg (0.9) versus placebo (2.1); occurrence of IBD and psoriasis were low or absent.

Conclusion

In patients with spondyloarthritis, development of EMMs was generally low with upadacitinib 15 mg. Uveitis was numerically lower in patients treated with upadacitinib 15 mg versus placebo, and particularly in r‐axSpA. Regardless of treatment in r‐axSpA, having a history of uveitis appeared to predispose patients for future uveitis events. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticHeterocyclic Compounds, 3-RingAxial SpondyloarthritisUveitisAntirheumatic AgentsHumansMaleFemaleAdultAdalimumabMiddle AgedInflammatory Bowel DiseasesPsoriasis

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingAdalimumabAntirheumatic Agents

Autor:innen und Institutionen

  • University of Toronto, Toronto, Ontario, Canada, and Charité-Universitätsmedizin, Berlin, Germany.
  • AbbVie, Inc, North Chicago, Illinois.
  • Ghent University Hospital and Ghent University, Ghent, Belgium.
  • Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
  • University of Glasgow, Glasgow, United Kingdom.
  • Washington University School of Medicine, St. Louis, Missouri.

ORCID-Profile: Denis Poddubnyy, Dirk Elewaut, Stefan Siebert, Michael Paley

Förderung

  • AbbVie

Zitieren

APA

Poddubnyy, D., Parikh, B., Elewaut, D., Navarro-Compán, V., Siebert, S., Paley, M., Coombs, D., Lagunes, I., Biljan, A., Nakasato, P., Wung, P., & Lubrano, E. (2025). Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.43069

Vancouver

Poddubnyy D, Parikh B, Elewaut D, Navarro-Compán V, Siebert S, Paley M, et al. Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis & Rheumatology. 2025. doi:10.1002/art.43069

BibTeX
@article{Poddubnyy2025,
  author = {Poddubnyy, Denis and Parikh, Bhumik and Elewaut, Dirk and Navarro-Compán, Victoria and Siebert, Stefan and Paley, Michael and Coombs, Derek and Lagunes, Ivan and Biljan, Ana and Nakasato, Priscila and Wung, Peter and Lubrano, Ennio},
  title = {Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43069}
}
Kostenlos starten →